Clinical Trials · NCT01733758
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 494
- Start date
- Feb 2013
- Locations
- 74 sites, Japan
- Primary endpoint
- Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24